Loading...
•
Jun 30, 2023
Fate Therapeutics Q2 2023 Earnings Report
Reported financial results and business updates for the second quarter of 2023.
Key Takeaways
Fate Therapeutics reported $0.9 million in revenue for Q2 2023 and ended the quarter with $385.2 million in cash, cash equivalents, and investments. The company is advancing its FT522, FT819, and FT576 programs and plans to submit an IND application for FT825/ONO-8250 in the second half of 2023.
Phase 1 study start-up is ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma.
IND submission planned in 2H23 under ONO collaboration for FT825/ONO-8250, a HER2-targeted CAR T-cell Program.
Dose escalation is ongoing in Phase 1 studies of FT819 CD19-targeted 1XX CAR T-cell Program for B-cell Malignancies and of FT576 BCMA-targeted CAR NK Cell Program for Multiple Myeloma.
Ended 2Q23 with $385 million in cash, cash equivalents, and investments, supporting runway into 2H25.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Fate Therapeutics is focused on advancing its iPSC-derived cellular immunotherapies and plans to submit an IND application for FT825/ONO-8250 in the second half of 2023.